Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes

February 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 2
Volume 15
Issue 2

In the largest prospective study of cigarette smoking and colorectal cancer mortality, researchers from the American Cancer Society report finding strong evidence that cancers of the colon and rectum are, in part, smoking related.

In the largest prospective study of cigarette smokingand colorectal cancer mortality, researchers from theAmerican Cancer Society report finding strong evidence that cancers of the colonand rectum are, in part, smoking related.

An analysis of the American Cancer Society’s Cancer PreventionStudy II appeared in a recent issue of the Journal of the National CancerInstitute (92:1888-1896, 2000). It concluded that not only is long-termcigarette smoking associated with an elevated risk of dying of colorectalcancer, but that about 12% of 1997 deaths from this cancer may be attributableto cigarette smoking.

Lowest Rates Among Nonsmokers

Ann Chao, PhD, Michael J. Thun, MD, and colleagues at theAmerican Cancer Society report that colorectal death rates were highest amongcurrent smokers and lowest among those who never smoked. "Clear benefitswere also observed among those people who had quit smoking; the longer ago, thehigher the benefit," said Dr. Chao.

In the study, current male smokers had a 32% higher death ratethan nonsmokers, and current female smokers had a death rate of 41%. The higherdeath rates increased with duration of the habit and with the number ofcigarettes smoked daily.

The rates were higher for current smokers who began smokingcigarettes at younger ages, than among those who smoked longer and morecigarettes per day.

Study Data

The Cancer Prevention Study II began enrolling approximately1 million Americans in 1982. Dr. Chao and her coauthors analyzed data on312,332 men and 469,019 women, among whom 4,432 died from either colon or rectalcancer. Data from these participants were controlled for a number of potentiallyconfounding variables including alcohol use, physical activity, family historyof colorectal cancer, vitamin use, and dietary factors.

"The size of the study allowed us to examine, in detail,gradients in smoking behavior separately in former and current smokers,"said Dr. Chao. "It also permitted us to estimate the percentage ofsmoking-related colorectal cancer deaths in the general population, which wouldhave been about 12% in 1997, or more than 6,800 people for that year," shesaid.

"The smoking epidemic in women began decades later than inmen," said Michael J. Thun, MD, vice president of epidemiology andsurveillance research for the American Cancer Society. "This may explain,in part, why the trends in colorectal cancer incidence and death rates differedbetween genders during the 1950s, 1960s, and 1970s, with male rates being higherthan female rates. As the smoking rates increased for women, the colorectalrates became very similar for both genders," said Dr. Thun. 

Articles in this issue

Book Review: Comprehensive Cancer Care: Integrating Alternative, Complementary, and Conventional Therapies
Study Details Use of Amifostine in Radiation Setting
Declines in Lung Cancer Rates-California, 1988-1997
Medicare Approves PET for Additional Cancers
Study Contributes to Evolution of Sentinel Lymph Node Biopsy for Melanoma
The Breast: Comprehensive Management of Benign and Malignant Diseases, Second Edition
Topotecan Active as First-Line Combination Therapy for Advanced Non-Small-Cell Lung Cancer
Promising Results With Motexafin for Brain Metastases and Glioblastoma Multiforme
Chemoradiotherapy Followed by Docetaxel May Increase Life Expectancy in Non-Small-Cell Lung Cancer Patients
Medicare Bill Expands Cancer Screening
Researchers Able to Predict Which Breast Cancer Patients Are at Highest Risk of Bone Metastases
Letrozole Approved as First-Line Treatment for Advanced Breast Cancer in Postmenopausal Women
American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes
Painful Osteoblastic Metastases: The Role of Nuclear Medicine
Corticosteroids in Advanced Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

Kristi Rosa
July 13th 2025
Article

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC

Roman Fabbricatore
July 10th 2025
Article

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Related Content

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

Kristi Rosa
July 13th 2025
Article

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC

Roman Fabbricatore
July 10th 2025
Article

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.